drug-discovery

Nature Reviews Drug Discovery, Published online: 02 September 2026; doi:10.1038/d41573-026-00146-x Click chemistry platform enhances ADC tumour targeting

Emerging and re-emerging infections expose a persistent mismatch between the speed of pathogen evolution and the pace of therapeutic development. Conventional two-dimensional cultures are scalable but poorly reproduce tissue architecture, whereas animal models may not capture human-specific tropism, immunity, pharmacokinetics, or toxicity. Human organoids and organ-on-chip systems offer complemen…

[Cell Reports] Researchers developed a patient-derived liver cancer organoid platform for high-throughput drug screening, identifying promising drug candidates and combination therapies across heterogeneous tumors.

(MIT Technology Review) – Patents can only name humans as inventors. For now. Insilico leads a pack of companies using AI to rapidly come up with drug ideas humans might never think of, potentially speeding the race to new cures. … Read More

Small molecules are the basis of most medicines and crop-protection products in use today, and account for the

Quinazoline scaffolds are widely recognized in drug discovery for their diverse pharmacological profiles, and several quinazoline derivatives have been reported as phosphodiesterase 7A (PDE7A) inhibitors with potential anti-inflammatory effects. This study aimed to synthesize novel quinazoline derivatives, evaluate their anti-inflammatory activity and investigate their computationally predicted b…

Drug-target interaction prediction can help researchers explain mechanisms of action, identify candidate targets, reposition existing medicines and prioritize compounds before costly laboratory work.

Artificial intelligence is reshaping one of drug discovery's most consequential questions: which compounds interact with which biological targets, and how strongly. A new review maps the fast-moving landscape of artificial intelligence (AI)-driven drug-target interaction (DTI) prediction, showing how the field has progressed from hand-crafted molecular features to deep learning, graph-based model…

There has been a growing focus on ‘molecular chameleons’ possessing structural flexibility; compounds that can dynamically adjust their conformations depending on the characteristics of the medium to either conceal or reveal polar parts in aqueous/lipidic environments. Drug discovery has shifted in the past few decades toward more complex molecules, such as cyclic and macrocyclic peptides, as wel…

Open Discovery Challenge: How to Build a Verifiable Judge for AI-Designed Malaria Drugs Generative models can propose thousands of plausible molecules in a day. The harder question is no longer whether an AI can draw a molecule. It is whether anyone can tell if that molecule is potent, selective, safe enough to investigate, and possible to synthesize. That is the premise of the Open Discovery Cha…

Nature Communications, Published online: 14 August 2026; doi:10.1038/s41467-026-76252-6 In this work, researchers show that activating cells before imaging reveals drug effects undetected under standard conditions, identifying unreported phenotypes for hundreds of compounds and identifying a natural product as a glucocorticoid receptor modulator.

Nature Reviews Drug Discovery, Published online: 12 August 2026; doi:10.1038/d41573-026-00136-z Oncolytic virus nabs FDA approval

Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership to accelerate drug discovery and modernise Novo Nordisk’s operations through agentic AI and cloud technologies. As part of the partnership, Novo Nordisk and AWS have created a co-innovation hub in London where engineers and...

Evotec SE announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabi...

Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug disco...

Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker’s post-genomic solutions for disease biology research, as well as for drug disco...

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates.